Align Technology guidance update and what it could mean for investors

Align Technology (ALGN) issued new earnings guidance for the third quarter and full year 2026 on July 29, alongside second quarter results and a buyback update, giving investors fresh data points to assess the stock.

Guidance for softer third quarter revenue, one time restructuring charges and the recent product updates around Align Technology’s digital platform appear to be feeding into mixed sentiment. The 1-year total shareholder return is 23.8%, but the 3-year total shareholder return has declined 51.7% and the 5-year total shareholder return has fallen 74.9%. This suggests long term momentum has faded even as the year to date share price return of 10.8% points to some recovery.

If this kind of earnings and product news has you thinking about where else growth or rerating potential might sit in healthcare, it could be worth scanning a curated list of 41 healthcare AI stocks

Align Technology appears to be a solid business on the product and earnings side. However, the share price has fallen sharply over three and five years. After the latest guidance and buyback activity, is the current valuation actually attractive?

Most Popular Narrative: 17.3% Undervalued

The most followed narrative on Align Technology puts fair value at $209.07 compared with the last close of $172.89, framing the stock as materially discounted and anchored in detailed assumptions about growth, margins and required return.

The continued expansion of clinical indications for Invisalign (such as Invisalign First for teens/kids and palate expanders) and the increasing adoption by general practitioner dentists are broadening Align's addressable market, positioning the company for higher long-term revenues and double-digit earnings growth as these new segments mature.

Want to see why this narrative still supports a higher fair value for Align Technology? The core rests on moderate revenue growth, improving margins and a tighter future earnings multiple. Curious how those pieces fit together into a $209 valuation and a specific discount rate? The full narrative walks through every step of that math.

Result: Fair Value of $209.07 (UNDERVALUED)

However, investors in Align Technology still need to weigh EU antitrust outcomes and weaker demand for higher margin scanner systems, which could pressure both growth assumptions and future P/E multiples.

Another view on Align Technology’s valuation

The first narrative frames Align Technology as 17.3% undervalued based on analyst earnings forecasts and a target P/E of 24.8x. Yet on today’s numbers, the stock trades on a 29.9x P/E, roughly in line with its fair ratio of 29.9x and slightly above the US Medical Equipment industry at 29x. That suggests the market may already be pricing in a fair amount of optimism. Is this a margin of safety, or a sign that expectations leave less room for error?

Next Steps

Given the mixed signals around Align Technology, do you feel the balance tilts more to risk or reward right now? Act while the details are still fresh and review both sides of the story so you can reach your own conclusion with 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Align Technology?

If Align Technology has you thinking more broadly about your portfolio, now is the moment to widen your search with focused stock ideas tailored to different goals.

• Target potential mispricings across the market by scanning the 53 high quality undervalued stocks that match solid fundamentals with lower valuations.
• Strengthen your income stream by reviewing the 7 dividend fortresses that combine higher yields with an emphasis on resilience.
• Reduce portfolio stress by concentrating on the 82 resilient stocks with low risk scores that rate well on financial stability and risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.